Condition: Non-squamous NSCLC · Sponsor: Jair Bar, M.D., Ph.D.
This study is a single-arm phase II study of neoadjuvant osimertinib as monotherapy for the treatment of patients with resectable stage II-III non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) sensitizing mutation (L858R or deletion in exon 19 \[Ex19del\]).
This description comes directly from the study's public registry record.
Sheba medical center · +972546288901 · Jair.Bar@sheba.health.gov.il
Always discuss trial participation with your own doctor first.
| Sheba Medical Center | Ramat Gan, Israel, Israel | Recruiting |
| Sheba Medical Center, Jusidman Cancer Center | Ramat Gan, Israel, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06206850